Who is sponsoring NCT05089591?

NCT05089591 is sponsored by Prim. Prof. Dr. Oliver Findl, MBA.

What drugs are being tested in NCT05089591?

Interventions in NCT05089591: Intense Pulsed Light therapy, Sham Treatment.

What condition does NCT05089591 study?

NCT05089591 studies Meibomian Gland Dysfunction.

Is NCT05089591 still recruiting?

NCT05089591 is currently status unknown. Last updated 22 October 2021.

Last reviewed 2021-10-22 · How we verify

NCT05089591

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Intense Pulsed Light in Meibomian Gland Dysfunction

Status unknown NA Last updated 22 October 2021

What this trial tests

NA trial testing Intense Pulsed Light therapy in Meibomian Gland Dysfunction in 38 participants. Status unknown.

Timeline

20 October 2021

Primary endpoint
20 October 2022

1 November 2022

Quick facts

Lead sponsor	Prim. Prof. Dr. Oliver Findl, MBA
Phase	NA
Status	Status unknown
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	double
Primary purpose	treatment
Enrollment	38
Start date	20 October 2021
Primary completion	20 October 2022
Estimated completion	1 November 2022
Sites	1 location across Austria

Drugs / interventions tested

Intense Pulsed Light therapy
Sham Treatment — full drug profile →

Conditions studied

Meibomian Gland Dysfunction — all drugs for Meibomian Gland Dysfunction →

Sponsor

Prim. Prof. Dr. Oliver Findl, MBA

Who can join

18 and older, any sex, with Meibomian Gland Dysfunction. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Meibomian gland dysfunction (MGD) is a major cause of dry eye disease (DED). Up to 86% of patients suffering from DED also show signs of MGD. Traditional treatment of MGD is based on eye lid hygiene and massage in combination with intensive usage of lubricants. Recently, a novel technology the intense pulsed light (IPL) therapy was introduced, which shows promising results in patients with meibomian gland dysfunction. Originating from field of dermatology, subjecting improvement of dry eye symptoms was recognized after the treatment of facial rosacea using IPL. Different hypotheses exist how IPL treatment might improve the situation in the dry eye patient. Warming of the eyelid, due to the light application and reduction of bacterial load are two possible mode of actions. Further, the used wavelengths in IPL may be modified that the light is only absorbed by oxygenated haemoglobin, which lead to an obliteration of telangiectasia and reduced inflammation on the lid margin. This principal is applied in the treatment of facial rosacea. Aim of this study is to investigate the effect of IPL therapy in patients with MGD on dry eye parameters as well as subjective complaints.

Publications & conference data

1 peer-reviewed publication reference this trial (live from Europe PMC):

Safety and efficacy of a novel intense pulsed light system in patients with meibomian gland dysfunction: a randomized, double-masked, intra-individual controlled study.
Schlatter A, Palkovits S, Amir-Asgari S, Ruiss M, et al · · 2025 · PMID 40524073 · DOI 10.1007/s10792-025-03622-2

Verify or expand the search:

Other recruiting trials for Meibomian Gland Dysfunction

Currently open trials in the same condition.

NCT06220474 — Therapeutic Efficacy and Safety of Non-Invasive RF Treatment in Refractory MGD · NA · recruiting
NCT06371300 — Photobiomodulation With REd vs BluE Light (REBEL) · NA · recruiting
NCT06054217 — Effect of an Exploratory Vehicle on Meibomian Gland Dysfunction in Patients With Demodex · Phase 2 · active not recruiting
NCT03652337 — Meibomian Gland Dysfunction Management · NA · active not recruiting

Other Prim. Prof. Dr. Oliver Findl, MBA trials

Trials by the same sponsor.

NCT07425626 — Brillouin Scanning in Cataractous Eyes · active not recruiting
NCT06624826 — Visual Performance of an Extended Depth of Focus IOL in an Emmetropic or Monovision Modality · NA · recruiting
NCT06459284 — Instrument Tissue Interaction at the Grasp Site During Membrane Peeling of Epiretinal Membranes · completed
NCT06948851 — New Postoperative Intraretinal Cystoid Changes After Vitrectomy With Membrane Peeling Due to Epiretinal Membranes · active not recruiting
NCT07436247 — Pseudophakic Eyes With Presbyopia-correcting IOLs: OCT Biometry and Pyramid Aberrometry · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT05089591 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Prim. Prof. Dr. Oliver Findl, MBA
Last refreshed: 22 October 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05089591.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing